Scottish Medicines Consortium (SMC)

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Gilead Sciences’ Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. The drug has been accepted for the treatment of chronic HDV infection in adult patients with evidence of significant fibrosis, whose disease has […]

Following a resubmission from manufacturer Merck, the Scottish Medicines Consortium (SMC) has now approved Tepmetko (tepotinib) for use on the NHS in Scotland.   It is recommended for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.   This change was made following […]

The Scottish Medicines Consortium (SMC) has updated its advice for AstraZeneca’s Lokelma (sodium zirconium cyclosilicate [SZC]) for adult patients with hyperkalaemia in Scotland.   Patients can now access SZC in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care.  SZC is already used within NHS Scotland for hyperkalaemia as outpatient care […]

The Scottish Medicines Consortium (SMC) has ruled Idefirix (imlifidase) clinically and cost-effective in highly sensitised adult patients prior to kidney transplant from a deceased donor.  The recommendation, which follows a positive ruling by the National Institute of Health and Care Excellence (NICE), marks an important milestone as highly sensitised patients are currently highly unlikely to […]

The first new treatment in 20 years that prevents a common, painful side-effect in patients with sickle cell disorder (SCD) has been issued interim acceptance by the Scottish Medicines Consortium (SMC).  The SMC issued interim acceptance for Novartis UK’s Adakveo for use in NHS Scotland as a treatment option for the prevention of recurrent vaso-occlusive […]